Antitumor and Immunopotentiating Activity of Polysaccharide PST001 Isolated from the Seed Kernel of Tamarindus indica: An In Vivo Study in Mice

Table 2

Tumor and hematological characteristics in mice injected with DLA on day 1 followed by PST001/drug administration for 14 days and dissected on 15th day (Group 2).

Concentration	DLA control	PST 200 mg/kg	CTX 50 mg/kg	PST + CTX
Tumor volume (mL)	9 ± 0.3	4.5±0.29 ***	4 ± 0.18***	3.9±0.23 ***
Body weight (g)	30.56±2.2	28.32±1.5 **	26.8±2.5 **	25.7±1.1 ***
PCV (mL)	3 ± 0.24	1.2±0.1 ***	0.8±0.1 ***	0.7±0.09 ***
Mean survival time (Days)	20 ± 1	31 ± 2***	35 ± 1***	37 ± 2***
% Increase in life span (ILS)	—	55 ± 1.4***	75 ± 0.96***	85 ± 1.7***
Tumor cell count (10^6 cells/mL)	150 ± 1.7	45 ± 1***	33 ± 0.95***	32 ± 0.62***
Percentage of viable cells	92 ± 1	77 ± 2***	72 ± 1***	70 ± 2.6***
Percentage of nonviable cells	8 ± 1	23 ± 1.7***	28 ± 2***	30 ± 1.7***
Hb (G%) (12.2–16.2) gm/dL	9 ± 0.26	10.8±0.4 *	11 ± 0.23**	11.5±0.3 **
RBC (Million/cmm) (7–12.5) × 10^6/mm^3	3.3±0.2	3.9±0.45^ns	4±0.18^ns	4.2±0.6^ns
TC (c/mm) (5100–11600)	12000 ± 507	9700 ± 360***	9000 ± 264***	8500 ± 300***
Platelets (/cmm) (160000–410000)	150000±1322	200000±264 ***	205000±1479 ***	215000±500 ***

Data were expressed as mean ± SD (𝑛=6) on day 15 of the experiment. Statistically significant differences are at *𝑃<0.05, **𝑃<0.01, ***𝑃<0.001; ns is the nonsignificant, as compared with control group.